Direkt zum Inhalt
Merck
  • Circulating concentrations of di(2-ethylhexyl) phthalate and its de-esterified phthalic acid products following plasticizer exposure in patients receiving hemodialysis.

Circulating concentrations of di(2-ethylhexyl) phthalate and its de-esterified phthalic acid products following plasticizer exposure in patients receiving hemodialysis.

Toxicology and applied pharmacology (1985-06-30)
G M Pollack, J F Buchanan, R L Slaughter, R K Kohli, D D Shen
ZUSAMMENFASSUNG

The degree of exposure to the plasticizer di(2-ethylhexyl) phthalate (DEHP) was assessed in 11 patients undergoing maintenance hemodialysis for the treatment of renal failure. The amount of DEHP leached from the dialyzer during a 4-hr dialysis session was estimated by monitoring the DEHP blood concentration gradient across the dialyzer. Circulating concentrations of the biologically active products of DEHP de-esterification, viz., mono(2-ethylhexyl) phthalate (MEHP) and phthalic acid, were also determined during the dialysis session. On the average, an estimated 105 mg of DEHP was extracted from the dialyzer during a single dialysis session, with a range of 23.8 to 360 mg. The rate of extraction of DEHP from the dialyzer was correlated with serum lipid content as expressed by the sum of serum cholesterol and triglyceride concentrations (r = +0.65, p less than 0.05). Time-averaged circulating concentrations of MEHP during dialysis (1.33 +/- 0.58 micrograms/ml) were similar to those of DEHP (1.91 +/- 2.11 micrograms/ml). Blood concentrations of phthalic acid (5.22 +/- 3.94 micrograms/ml) were higher than those of the esters. The length of time patients had been receiving regular dialysis treatment was not a determinant of circulating concentrations of DEHP or MEHP. In contrast, time-averaged circulating concentrations of phthalic acid correlated strongly with the duration (in years) of dialysis treatment (r = +0.92, p less than 0.001). The results indicated substantial exposure to DEHP during hemodialysis and that the de-esterified products of DEHP are present in significant concentrations in the systemic circulation. Further study is needed to assess the contribution of these metabolites to the biological actions of DEHP in man.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Retinol, synthetic, ≥95% (HPLC), (Powder or Powder with Lumps)
Sigma-Aldrich
Betain -Lösung, 5 M, PCR Reagent
Sigma-Aldrich
Oxalsäure, 98%
Sigma-Aldrich
L-Prolin, from non-animal source, meets EP, USP testing specifications, suitable for cell culture
Sigma-Aldrich
Zink, dust, <10 μm, ≥98%
Sigma-Aldrich
Betain, BioUltra, ≥99.0% (NT)
Sigma-Aldrich
Retinol, BioXtra, ≥97.5% (HPLC), ~3100 U/mg
Sigma-Aldrich
Glycolsäure, ReagentPlus®, 99%
Sigma-Aldrich
Zink, granular, 20-30 mesh, ACS reagent, ≥99.8%
Sigma-Aldrich
Betain, ≥98% (perchloric acid titration)
Sigma-Aldrich
Oxalsäure, ReagentPlus®, ≥99%
Sigma-Aldrich
Zink, powder, <150 μm, 99.995% trace metals basis
Sigma-Aldrich
p-Cresol, 99%
Sigma-Aldrich
L-Prolin, ReagentPlus®, ≥99% (HPLC)
SAFC
L-Prolin
Sigma-Aldrich
L-Prolin, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
Trans-4-Hydroxy-L-Prolin, ≥99%
Sigma-Aldrich
Oxalsäure, purified grade, 99.999% trace metals basis
Sigma-Aldrich
Retinol, ≥95.0% (HPLC), ~2700 U/mg
Sigma-Aldrich
Oxalsäure, puriss. p.a., anhydrous, ≥99.0% (RT)
Sigma-Aldrich
Zink, foil, thickness 0.25 mm, 99.9% trace metals basis
Sigma-Aldrich
Phthalsäure, ACS reagent, ≥99.5%
Sigma-Aldrich
L-Prolin, 99%, FCC, FG
Sigma-Aldrich
DL-Homocystein, ≥95% (titration)
Sigma-Aldrich
Zink, nanopowder, 40-60 nm avg. part. size, ≥99% trace metals basis
Sigma-Aldrich
Zink, purum, powder
Sigma-Aldrich
p-Cresol, ≥99%, FG
Sigma-Aldrich
Trans-4-Hydroxy-L-Prolin, BioReagent, suitable for cell culture, ≥98.5%
Sigma-Aldrich
Glycolsäure -Lösung, technical grade, 70 wt. % in H2O
Sigma-Aldrich
Zink, granular, 30-100 mesh, 99%